JP2013536235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536235A5 JP2013536235A5 JP2013526084A JP2013526084A JP2013536235A5 JP 2013536235 A5 JP2013536235 A5 JP 2013536235A5 JP 2013526084 A JP2013526084 A JP 2013526084A JP 2013526084 A JP2013526084 A JP 2013526084A JP 2013536235 A5 JP2013536235 A5 JP 2013536235A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- groups
- alkoxy
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 67
- -1 hydroxy, amino Chemical group 0.000 claims 24
- 125000003545 alkoxy group Chemical group 0.000 claims 23
- 125000003386 piperidinyl group Chemical group 0.000 claims 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 125000002757 morpholinyl group Chemical group 0.000 claims 15
- 125000004193 piperazinyl group Chemical group 0.000 claims 15
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 10
- 125000002098 pyridazinyl group Chemical group 0.000 claims 10
- 125000004076 pyridyl group Chemical group 0.000 claims 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 10
- 125000002393 azetidinyl group Chemical group 0.000 claims 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000002883 imidazolyl group Chemical group 0.000 claims 9
- 125000000335 thiazolyl group Chemical group 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 8
- 125000003373 pyrazinyl group Chemical group 0.000 claims 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims 8
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 6
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000002541 furyl group Chemical group 0.000 claims 5
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000002971 oxazolyl group Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000001425 triazolyl group Chemical group 0.000 claims 5
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical group C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 4
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 150000002617 leukotrienes Chemical class 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 0 *C(*)(c1n[o]c(*)n1)c1ccc(*)cc1* Chemical compound *C(*)(c1n[o]c(*)n1)c1ccc(*)cc1* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37718110P | 2010-08-26 | 2010-08-26 | |
| US61/377,181 | 2010-08-26 | ||
| US201161511247P | 2011-07-25 | 2011-07-25 | |
| US61/511,247 | 2011-07-25 | ||
| PCT/US2011/048743 WO2012027322A1 (en) | 2010-08-26 | 2011-08-23 | Oxadiazole inhibitors of leukotriene production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536235A JP2013536235A (ja) | 2013-09-19 |
| JP2013536235A5 true JP2013536235A5 (OSRAM) | 2014-10-09 |
| JP5862669B2 JP5862669B2 (ja) | 2016-02-16 |
Family
ID=44533215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526084A Active JP5862669B2 (ja) | 2010-08-26 | 2011-08-23 | ロイコトリエン産生のオキサジアゾール阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8580829B2 (OSRAM) |
| EP (1) | EP2609092B1 (OSRAM) |
| JP (1) | JP5862669B2 (OSRAM) |
| WO (1) | WO2012027322A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011292285A1 (en) | 2010-08-16 | 2013-01-31 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| EP2609092B1 (en) | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
| WO2012040137A1 (en) * | 2010-09-23 | 2012-03-29 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| PH12013500545A1 (en) * | 2010-09-23 | 2013-05-06 | Boehringer Ingelheim Int | Oxadiazole inhibitors of leukotriene production |
| WO2013116182A1 (en) * | 2012-01-31 | 2013-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as inhibitors of leukotriene production |
| AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| MX2015000794A (es) | 2012-07-18 | 2015-10-12 | Univ Saint Louis | Derivados de aminoácido beta como antagonistas de integrina. |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| EP3070085B1 (en) * | 2013-02-04 | 2019-01-09 | Janssen Pharmaceutica NV | Flap modulators |
| RS59911B1 (sr) | 2013-10-14 | 2020-03-31 | Eisai R&D Man Co Ltd | Selektivno supstituisana jedinjenja hinolina |
| CA2920791C (en) | 2013-10-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| CN105899504A (zh) * | 2014-01-21 | 2016-08-24 | 豪夫迈·罗氏有限公司 | 用于治疗和预防呼吸道合胞病毒感染的咪唑化合物 |
| AU2015270118C1 (en) | 2014-06-03 | 2019-11-28 | Idorsia Pharmaceuticals Ltd | Pyrazole compounds and their use as T-type calcium channel blockers |
| RU2729518C2 (ru) | 2015-12-30 | 2020-08-07 | Сент-Луис Юниверсити | Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина |
| TWI808952B (zh) | 2016-12-16 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 包含t型鈣通道阻斷劑之醫藥組合 |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| WO2019027855A1 (en) * | 2017-08-02 | 2019-02-07 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
| EP3661910B1 (en) | 2017-08-02 | 2023-08-16 | Merck Sharp & Dohme LLC | Novel substituted pyridine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| JP2023140319A (ja) | 2022-03-22 | 2023-10-04 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20020096A2 (en) | 1999-08-06 | 2005-10-31 | Janssen Pharmaceutica N.V. | Interleukin-5 inhibiting 6-azauracil derivatives |
| US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
| AU2005295646B2 (en) | 2004-10-18 | 2008-11-20 | Merck Sharp & Dohme Corp. | Diphenyl substituted alkanes as flap inhibitors |
| US7977359B2 (en) * | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| JP2009533435A (ja) * | 2006-04-11 | 2009-09-17 | メルク エンド カムパニー インコーポレーテッド | ジアリール置換アルカン |
| EP2452683A3 (en) | 2006-06-26 | 2012-08-22 | Amgen Inc. | Methods for treating atherosclerosis |
| WO2008030369A1 (en) | 2006-09-01 | 2008-03-13 | Merck & Co., Inc. | Inhibitors of 5 -lipoxygenase activating protein ( flap) |
| CA2683948A1 (en) | 2007-04-20 | 2008-10-30 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AU2008266960A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Diphenyl substituted alkanes |
| JP2011500563A (ja) | 2007-10-10 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | ジフェニル置換されたシクロアルカン |
| CA2741666C (en) * | 2008-10-31 | 2017-04-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| EP2393811A1 (en) | 2009-02-04 | 2011-12-14 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
| AU2011252974A1 (en) | 2010-05-12 | 2012-12-13 | Vanderbilt University | Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| AU2011292285A1 (en) * | 2010-08-16 | 2013-01-31 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| EP2609092B1 (en) | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
| WO2012040137A1 (en) * | 2010-09-23 | 2012-03-29 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| PH12013500545A1 (en) * | 2010-09-23 | 2013-05-06 | Boehringer Ingelheim Int | Oxadiazole inhibitors of leukotriene production |
-
2011
- 2011-08-23 EP EP11749686.9A patent/EP2609092B1/en active Active
- 2011-08-23 US US13/215,654 patent/US8580829B2/en active Active
- 2011-08-23 JP JP2013526084A patent/JP5862669B2/ja active Active
- 2011-08-23 WO PCT/US2011/048743 patent/WO2012027322A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536235A5 (OSRAM) | ||
| JP2013534245A5 (OSRAM) | ||
| JP2013542994A5 (OSRAM) | ||
| CN110475775B (zh) | 4-吡啶酮化合物或其盐、包含4-吡啶酮化合物的药物组合物及剂 | |
| AU2012313094B2 (en) | Pyrazole carboxamides as janus kinase inhibitors | |
| CA2903288C (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP7068295B2 (ja) | Ｂ型肝炎ウイルス感染症の処置及び予防のための新規なテトラヒドロピリドピリミジン | |
| JP2011525192A5 (OSRAM) | ||
| JP2013537908A5 (OSRAM) | ||
| JP2009263394A5 (OSRAM) | ||
| AU2014234906B2 (en) | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | |
| JP2013510120A5 (OSRAM) | ||
| JP2006508935A5 (OSRAM) | ||
| WO2009117269A1 (en) | Substituted 4-hydroxypyrimidine-5-carboxamides | |
| JP2012529522A5 (OSRAM) | ||
| JP2010506850A5 (OSRAM) | ||
| PH12015502114B1 (en) | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| CN103664897A (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| JP2016505021A5 (OSRAM) | ||
| JP2013512953A5 (OSRAM) | ||
| JP2012097115A5 (OSRAM) | ||
| JP2015504076A5 (OSRAM) | ||
| JP2009543795A5 (OSRAM) | ||
| JP2013540712A5 (OSRAM) | ||
| WO2016064935A1 (en) | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors |